2023-10-12 08:45 Regulatory
Biovica, active in cancer monitoring, today announces the signing of an agreement providing access to DiviTum TKa to appropriate patients treated at a leading cancer center in Florida. This center in Florida is part of a large and well renowned organization...
2023-09-28 10:30 Regulatory
Biovica, active in cancer monitoring, today announces that the Center for Medicare & Medicaid Services (CMS) has issued a preliminary CLFS payment decision for DiviTum TKa to pursue the gap-fill process during 2024. The gap-fill process is an established...
2023-09-25 08:00 Regulatory
Biovica, active in cancer monitoring, today announces that the company has signed its second US hospital agreement for DiviTum® TKa with the largest healthcare provider in Missouri, a state covering about two percent of the US population. The healthcare...
2023-09-19 09:00 Regulatory
Biovica today announces that the company has entered into a commercial agreement with a leading healthcare provider that operates more than 30 hospital laboratories, primarily located in Arizona. The agreement will ensure access to DiviTum® TKa for...
2023-09-06 08:00 Regulatory Interim
Higher sales and commercial milestones achieved in the USA Significant events during the first quarter Significant events after the end of the period Webcast:When: 21 June 2023, 3 PM to 4 PM CETWhere: registration via lyyti: https://www.lyyti.in/Biovica_Q1_Earnings_call_2023__Live_Event_3956Broadcast...
2023-09-05 13:00 Regulatory
The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 5 September 2023 and the following resolutions were passed by the meeting. ADOPTION OF THE INCOME STATEMENT AND BALANCE SHEETThe...
2023-08-04 12:30 Regulatory
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the annual general meeting to be held on Tuesday 5 September 2023, at 10.00 CET in Conference Hubben's premises on Dag Hammarskjölds...
2023-07-31 08:00 Regulatory
Biovica today announces that the company has signed a commercial agreement with Occum Health for DiviTum® TKa in the US, making the blood test available to the more than 500 self-insured clients and key strategic partners. Occum Health is a healthcare...
2023-07-21 08:00 Regulatory
Biovica, active in cancer monitoring, today announces that the company has received a PLA code from the AMA (American Medical Association), an important milestone in the commercialization of DiviTum® TKa in the United States. The PLA code is a specific...

>4,500

Numbers of patients in studies

28

Publications

19

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No